Health Catalyst (NASDAQ:HCAT) Expected to Announce Quarterly Sales of $41.27 Million

Analysts predict that Health Catalyst (NASDAQ:HCAT) will report $41.27 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Health Catalyst’s earnings, with the highest sales estimate coming in at $42.00 million and the lowest estimate coming in at $40.60 million. The business is expected to issue its next quarterly earnings results on Tuesday, February 11th.

According to Zacks, analysts expect that Health Catalyst will report full year sales of $152.62 million for the current year, with estimates ranging from $152.10 million to $153.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $184.58 million, with estimates ranging from $182.85 million to $186.55 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. The firm had revenue of $39.40 million for the quarter, compared to analyst estimates of $37.77 million. Health Catalyst’s revenue for the quarter was up 19.8% compared to the same quarter last year.

A number of analysts have weighed in on the company. Leerink Swann assumed coverage on Health Catalyst in a research report on Monday, August 19th. They issued an “outperform” rating and a $55.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Health Catalyst in a research report on Monday, August 19th. They issued an “overweight” rating and a $50.00 price target for the company. William Blair assumed coverage on Health Catalyst in a research report on Monday, August 19th. They issued an “outperform” rating for the company. Evercore ISI assumed coverage on Health Catalyst in a research report on Monday, August 19th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Svb Leerink assumed coverage on Health Catalyst in a research report on Monday, August 19th. They issued an “outperform” rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $49.33.

Shares of NASDAQ:HCAT traded up $1.74 on Friday, reaching $36.12. The company had a trading volume of 138,379 shares, compared to its average volume of 340,130. Health Catalyst has a twelve month low of $26.00 and a twelve month high of $49.85. The company has a 50-day moving average of $30.60. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.27 and a quick ratio of 5.27.

Several institutional investors have recently bought and sold shares of the company. Dean Capital Investments Management LLC bought a new position in shares of Health Catalyst in the third quarter worth about $485,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Health Catalyst in the third quarter worth about $542,000. Emerald Advisers LLC bought a new position in shares of Health Catalyst in the third quarter worth about $631,000. California Public Employees Retirement System bought a new position in shares of Health Catalyst in the third quarter worth about $202,000. Finally, State of Tennessee Treasury Department bought a new position in shares of Health Catalyst in the third quarter worth about $316,000. Institutional investors and hedge funds own 7.28% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

Featured Article: What is the Hang Seng index?  

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.